Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald M Black

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Atherosclerosis Reports|February 4, 2003
The development of combination drugs for atherosclerosisDonald M Black
Current Atherosclerosis Reports|January 5, 2002
Gut-acting drugs for lowering cholesterolDonald M Black
Current Atherosclerosis Reports|February 4, 2003
Patient compliance is a critical factor in the effectiveness of cardiac preventionDonald M Black
The American Journal of Cardiology|April 8, 2003
Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterolDonald M Black
The American Journal of Cardiology|March 7, 2002
A discussion of modalities for assessing regression and progression in vascular diseaseDonald M Black
The American Journal of Cardiology|March 7, 2002
Documenting regression of atherosclerosis: practical approaches in drug developmentDonald M Black
Current Atherosclerosis Reports|January 5, 2002
A general assessment of the safety of HMG CoA reductase inhibitors (statins)Donald M Black
Current Atherosclerosis Reports|February 4, 2003
C-reactive protein and lipids may respond differently to statinsDonald M Black
Current Atherosclerosis Reports|February 4, 2003
Issues that led to the withdrawal of cerivastatinDonald M Black
Current Atherosclerosis Reports|January 5, 2002
Patients with acute coronary syndromes should received statinsDonald M Black, Evan A Stein
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Atherosclerosis Reports|February 4, 2003
The development of combination drugs for atherosclerosisDonald M Black
Current Atherosclerosis Reports|January 5, 2002
Gut-acting drugs for lowering cholesterolDonald M Black
Current Atherosclerosis Reports|February 4, 2003
Patient compliance is a critical factor in the effectiveness of cardiac preventionDonald M Black
The American Journal of Cardiology|April 8, 2003
Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterolDonald M Black
The American Journal of Cardiology|March 7, 2002
A discussion of modalities for assessing regression and progression in vascular diseaseDonald M Black
The American Journal of Cardiology|March 7, 2002
Documenting regression of atherosclerosis: practical approaches in drug developmentDonald M Black
Current Atherosclerosis Reports|January 5, 2002
A general assessment of the safety of HMG CoA reductase inhibitors (statins)Donald M Black
Current Atherosclerosis Reports|February 4, 2003
C-reactive protein and lipids may respond differently to statinsDonald M Black
Current Atherosclerosis Reports|February 4, 2003
Issues that led to the withdrawal of cerivastatinDonald M Black
Current Atherosclerosis Reports|January 5, 2002
Patients with acute coronary syndromes should received statinsDonald M Black, Evan A Stein
Pageof 3